A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
| 适应症 | Glioblastoma, Glioblastoma Multiforme |
|---|---|
| 分期 | 1期 |
| 申办方 | Bryan Allen |
| 状态 | 进行中（已停止招募） |
| 受试者人数 | 16 人 |
| 干预（药物） | Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide |
| 开始日期 | 2023年2月28日 |
| 完成日期 | 2025年5月13日 |
| 结果公布日 | 2026年7月20日 |
摘要
This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.
Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs)
| Cohort 1 | 2 Dose Limiting Toxicities |
|---|---|
| Cohort 2 | 0 Dose Limiting Toxicities |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed M — National Cancer Institute (NCI)